A Phase 4 interventional study of atorvastatin, Lipitor in Hypercholesteremia and Coronary Artery Disease, sponsored by Astellas Pharma Inc. Completed at 2 sites in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2011-11-17.
Sponsored by Astellas Pharma Inc · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies testing atorvastatin in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Hypercholesterolemia.
Among the 77 studies testing atorvastatin in Hypercholesterolemia, this one is the 57th largest by enrollment of the 75 interventional ones that give a count, is one of 28 in phase 4, and was the 17th registered.
1,179 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 77 studies testing atorvastatin in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →
Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 20 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 109 across 978 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 75 interventional studies. Of the 69 that completed or were terminated, 33 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 77 have an industry lead sponsor. The 10 most frequent:
Astellas Pharma Inc is the lead sponsor of 525 studies on the registry; 4 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 19 (68%) have results posted.
Astellas Pharma Inc has 2 studies filed under Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 77 studies testing atorvastatin in Hypercholesterolemia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy of intensive lipid-lowering therapy with Lipitor on the changes of characteristics of yellow coronary plaque in subjects with hypercholesteremia accompanying coronary artery disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Changes in plaque characteristics as observed by coronary angioscopy
(the amount of yellow plaque and grade shall be determined by the coronary angioscopic findings evaluation committee)
Changes in the volume and the echogenicity as observed by intravascular ultrasound
Rate of change in serum lipid level
Changes in the surface character and size of plaque as observed by coronary angioscopy (determined by the angioscopic findings evaluation committee)
This study is completed, as verified in Dec 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atorvastatin